Testosterone therapy and diabetes: read the trials by their endpoint

Testosterone therapy is not a diabetes-control prescription. The Endocrine Society recommends against using TRT to improve glycemic control in men with type 2 diabetes, even when testosterone is low. The TRAVERSE diabetes substudy found no significant glycemic or diabetes-progression benefit in its hypogonadal population. The Australian T4DM trial found a lower proportion meeting diabetes criteria at two years in a different population that included men with impaired glucose tolerance and men with newly diagnosed type 2 diabetes, all within a lifestyle program. Neither trial creates an FDA diabetes indication for testosterone.¹²³⁴

The confusion often begins with a genuine association: metabolic conditions and low testosterone can coexist. An association does not show that raising testosterone treats diabetes. A person may also have a valid testosterone-deficiency question and a separate diabetes-management plan. The two clinicians should know about each other without making one treatment do the other’s job.

Define the endpoint before comparing studies

The Endocrine Society’s recommendation 2.6 is precise: in men with type 2 diabetes and low testosterone, do not use testosterone as a means of improving glycemic control. It does not say that diabetes automatically forbids treatment for independently diagnosed hypogonadism. That decision has its own diagnostic and safety framework.¹

TRAVERSE found no diabetes benefit in its substudy

The TRAVERSE substudy included men with hypogonadism and prediabetes or diabetes, randomized to testosterone gel or placebo. Progression from prediabetes to diabetes did not differ significantly between groups; glycemic remission and glucose or HbA1c changes were similar among those with diabetes. The authors concluded that TRT alone should not be used to prevent or treat diabetes in this population.²

The trial has strengths: randomization, a placebo comparator, and many sites. It also studied a defined age, health profile and topical product. It is not a study of every injection or a prediction of one person’s glucose response. The central message is still clear: a clinic should not sell a TRT prescription as an established way to bring diabetes under control.

Why T4DM is not a contradiction that proves the opposite

T4DM enrolled Australian men with impaired glucose tolerance or newly diagnosed type 2 diabetes, without pathological hypogonadism. All entered a lifestyle program and were randomized to testosterone treatment or placebo over two years. Its coprimary outcomes were the proportion meeting diabetes criteria at two years and the change in two-hour oral glucose tolerance test results. A lower proportion in the testosterone arm met diabetes criteria at follow-up. That result combines possible prevention and reversion in this starting population; it is not simply a count of newly diagnosed cases. The study also reported a substantial hematocrit-monitoring signal and said durability, safety and cardiovascular effects warranted further study.³

This population was not identical to the men with diagnosed hypogonadism and diabetes in TRAVERSE. The treatment formulation, lifestyle program and paired primary endpoints also differ. A positive mixed prevention-and-reversion result in T4DM cannot be pasted into a claim that a South Florida testosterone clinic can treat established diabetes. Nor should TRAVERSE be used to pretend T4DM never found a signal. The useful synthesis is conditional: T4DM’s population-specific finding remains a research question, while current clinical guidance rejects TRT as glycemic-control therapy.

The hematocrit guide explains the blood-count issue that a marketing summary of T4DM may omit. A result that appears favorable on one endpoint still needs a safety record and a clearly identified indication.

Read the named product label

The cited testosterone cypionate injection label addresses certain male hypogonadism indications. It is not labeled as a treatment for type 2 diabetes. Its interaction text says androgen effects may decrease blood glucose and therefore insulin requirements in diabetic patients. That is a reason for prescriber coordination, not a reason to use the product as a glucose-lowering drug.⁴

Someone seeing a hormone practice while managing diabetes should bring both medicine lists and identify which clinician follows glucose-related outcomes. The testosterone prescriber should explain the hormone diagnosis and product, while the clinician managing diabetes should remain responsible for interpreting the metabolic record.

Questions that expose an overbroad claim

• Is the proposed TRT for a diagnosed testosterone deficiency or for “metabolic optimization”?
• What symptoms and repeat measurements support the hormone diagnosis?
• Does the clinic cite TRAVERSE’s diagnosed-deficiency population or T4DM’s mix of impaired glucose tolerance and newly diagnosed diabetes without pathological hypogonadism?
• Which product is proposed, and does its FDA label include a diabetes indication?
• Who monitors diabetes medicines, glucose trends and hematocrit if two care plans coexist?

These questions make trial evidence useful without turning it into treatment advice. At a hormone-therapy consultation, ask for separate written goals for the hormone and diabetes plans. A practice that can keep those goals distinct is better equipped to coordinate with the clinician already managing diabetes.